About Click Therapeutics
Click Therapeutics is redefining modern medicine by developing, validating, and commercializing software as prescription medical treatments for people with unmet medical needs. Operating at the intersection of biology and technology, Click combines neuroscience with the power of software to create a new way to treat disease. The company's platform-based approach targets diseases from multiple angles, combining scientifically proven therapies with proprietary neuromodulatory mechanisms of action to deliver clinically-meaningful interventions. Click develops two types of solutions: Prescription Digital Therapeutics (PDTs) that function as standalone software treatments, and Software-Enhanced Drugs (SE Drugs) that combine software with pharmacotherapy to deliver added clinical benefit compared to drug alone. Their platform can target any disease, symptom, or side effect with an underlying neurological or behavioral component, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. The company's products are regulated by the FDA as medical devices, with evidence-based treatment claims validated through rigorous randomized clinical trials. Their launched and FDA-authorized products include CT-152 (Rejoyn) for major depressive disorder, AspyreRx for type 2 diabetes, and CT-132 for episodic migraine. Click maintains ISO 13485:2016 certification for medical device quality management and ISO/IEC 27001:2022 certification for information security, demonstrating their commitment to delivering safe and effective digital treatments through a platform backed by over a decade of development.
Mission & Story
Mission
Redefining modern medicine with patient-centric digital treatments
Founding Story
Founded by David Benshoof Klein, who serves as Founder & CEO
Clinical Focus
Medical conditions and clinical areas addressed by Click Therapeutics.
Who It Serves
Milestones & Awards
Recent Milestones
CT-152 (Rejoyn) FDA cleared April 2024 and launched. AspyreRx FDA authorized for Type 2 Diabetes. CT-132 FDA authorized for episodic migraine. Partnership with Ultrahuman announced for biomarker-driven migraine management. Multiple Phase 3 trial results published in 2025.
Key Partnerships
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 48 →
AbleTo
AI-powered mental health and digital therapeutics platform delivering behavioral health interventions and therapy support.
Akili
Akili Interactive creates FDA-authorized digital therapeutics delivered through video game experiences to treat cognitive impairments. Their flagship products include EndeavorRx, the first FDA-approved prescription video game for children with ADHD, and EndeavorOTC for adults with ADHD.
Alma
Alma is a mental health care platform that connects clients with therapists who accept insurance across all 50 states. The company supports both clients seeking affordable therapy and mental health providers with practice management tools and insurance credentialing.
Alto Neuroscience
Alto Neuroscience develops biology-driven precision medicines for neuropsychiatric conditions. The company uses brain biology measurements to predict clinical response and identify patients most likely to benefit from their drug candidates.
BeMe Health
BeMe is a mobile mental health platform designed specifically for teens and young adults. The app provides a safe space for mood tracking, personalized content, live 1:1 coaching, and crisis support to improve emotional well-being and mental health.
Big Health
Big Health provides FDA-cleared digital therapeutics delivering cognitive behavioral therapy (CBT) for insomnia and anxiety. Their prescription products, SleepioRx and DaylightRx, serve health systems, health plans, and employers with evidence-based mental health solutions backed by 100+ peer-reviewed publications.
Blueprint Health
Blueprint provides an AI-powered assistant for mental health therapists that automates clinical documentation, generates treatment plans, and delivers clinical support. The platform works alongside existing EHRs or as a standalone AI-native EHR with integrated scheduling, telehealth, billing, and insurance management.
Boulder Care
Boulder Care provides telehealth-based addiction treatment for substance use disorder (SUD), including opioid use disorder (OUD) and alcohol use disorder (AUD). The company delivers whole-person, coordinated outpatient care through a secure mobile app, including medication-assisted treatment (MAT) with Suboxone and other medications, supported by dedicated care teams.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.